Catalent is a leading global provider of development and manufacturing services for pharma and consumer products, as well as advanced therapies in biologics, and cell and gene therapies.
Catalent’s Bloomington, Indiana site became a critical asset in the US Government’s supply chain response to the Covid-19 pandemic. Two capital projects were delivered in the midst of the pandemic, Project Mercury (FOYA award winner) and Project Apollo. Both of these assets were brand-new high-speed vial filling lines (600 units/minute) that were brought into service with record speed, in the middle of a situation where much of the world was on lockdown, and critical supply chains were stretched to their limits. This session will go into the scope of these projects, their execution models, and how the Catalent teams and their partners navigated the extremely challenging environments of late 2020 into 2021, to deliver these assets for patients.